Cancer Advisor

In this article From Viral Claims to Evidence-Based Protocols Cancer Metabolism: Beyond the Warburg Effect Metabolic Plasticity: Why Starving Cancer Isn't Simple Immunometabolism: Where Metabolism Meets Immunity Tumor Microenvironment: The Hidden Battlefield Diet, Fasting, and Metabolic Therapies: What the Evidence Says Repurposed Drugs and Natural Compounds The Microbiome Revolution Immunotherapy: The Real Breakthrough Inflammation, Insulin Resistance, and Cancer Risk The 7-Layer Evidence-Based Framework Final Verdict: What the Science Supports From Viral Claims to Evidence-Based Protocols The explosion of cancer content online has produced two dangerous extremes: conventional oncology portrayed as toxic and profit-driven, and alternative narratives offering simplistic cures with minimal evidence. Neither extreme serves patients. The future of oncology is neither rejection nor blind acceptance. It is integrative, systems-based medicine ...

Most people imagine cancer prevention as something slow, complicated, and highly disciplined: Clean diets. Gym routines. Supplements. Perfect consistency. That’s not how it usually works in real life. The most sustainable strategies are almost invisible. They take seconds—not hours. And two of the most powerful tools are: Habit stacking ( emphasized by the American Institute for Cancer Research -  AICR ) VILPA (Very Intense Light Physical Activity) ( JAMA Oncology ) Used together, they quietly reshape cancer risk over time. The Problem: Willpower Fails. Systems Don’t. Cancer risk is shaped over years—not days. Yet most prevention advice fails because it relies on: motivation memory lifestyle overhauls “starting Monday” energy That’s not how human behavior works. A more effective approach is simple: Attach tiny cancer-protective actions to things you already do every day. This is called habit stacking , a concept widely used in behavior change science and popularized in ...

Authors:  Ilyes Baghli 1 , William Makis 2 , Paul E. Marik 3 , Michael J. Gonzalez 4,5,6 , William B. Grant 7 , Ron Hunninghake 8 , Thomas E. Levy 8 , Homer Lim 9 , Richard Z. Cheng 10 , Igor Bondarenko 11 , Paul Bousquet 12 , Roberto Ortiz 13 , Mignonne Mary 14 , Dominic P. D’Agostino 15 , Pierrick Martinez 16 1  International Society for Orthomolecular Medicine, Toronto, ON, Canada 2  Alberta Health Services, Cross Cancer Institute, Edmonton, AB, Canada 3  Frontline COVID-19 Critical Care Alliance, Washington, DC, USA 4  University of Puerto Rico, Medical Sciences Campus, School of Public Health, San Juan, PR 5  Universidad Central del Caribe, School of Chiropractic, Bayamon, Puerto Rico 6  EDP University, Naturopathic Sciences Program, Hato Rey, Puerto Rico 7  Sunlight, Nutrition, and Health Research Center, San Francisco, CA, USA 8  Riordan Clinic, 3100 North Hillside, Wichita, KS, USA 9  Akesis Holistic Health, Manila, Philippines 1...

Abstract: Therapeutic resistance remains the primary cause of cancer-related mortality, driven by cancer cells' extraordinary metabolic plasticity and ability to remodel the tumor microenvironment. While traditional precision oncology focuses on genomic drivers, emerging evidence suggests that a multidimensional approach—integrating metabolism, immunity, and evolutionary selection pressures—is required for durable control. This article explores the Personalized Metabolic Oncology (PMO) framework and the Hybrid Orthomolecular Protocol, which utilize repurposed antiparasitic agents like ivermectin, fenbendazole, and mebendazole to target the mitochondrial-stem cell connection and metabolic vulnerabilities. By "stacking" evidence-based interventions including dietary modulation, orthomolecules, and repurposed drugs, clinicians can address cancer as a dynamic adaptive ecosystem. Keywords: Personalized Metabolic Oncology, Ivermectin, Fenbendazole, Therapeutic Resistance, Can...

Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....